Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers
This study has been completed.
Information provided by (Responsible Party):
First received: July 13, 2007
Last updated: May 31, 2012
Last verified: February 2011
The rationale of this study is to assess whether or not food affects the absorption of GW273225 into the blood of healthy male and female volunteers in order to evaluate whether or not this drug should be given at a certain time relative to the consumption of food.
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
||An Open, Randomised, Two-period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of GW273225 Administered Immediately After Food and Administered in the Fasted State to Healthy Male and Female Volunteers.
Primary Outcome Measures:
- Bioavailability and maximal concentration of the drug measured between 0 hours and 216 hours post dose. [ Time Frame: measured between 0 hours and 216 hours post dose ]
Secondary Outcome Measures:
- Time to maximal concentration measured between 0-216h post dose. Clinically relevant changes from baseline in clinical laboratory parameters (48 hours post dose), ECGs (0-48h post dose) and vital signs (0-48 hours post dose and any AEs during the study. [ Time Frame: Time to maximal concentration measured between 0-216h post dose ]
| Study Start Date:
Other Name: GW273225
|Ages Eligible for Study:
||18 Years to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Healthy male or female subjects aged 18-55 years, inclusive.
- Body weight 45-100kg and BMI 19-29.9 kg/m2 inclusive.
- Post-menopausal females (longer than two years). Or Pre-menopausal females with a documented hysterectomy and/or bilateral oophorectomy, the latter only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- Female subjects of child bearing potential willing to participate commit to use a double-barrier method of contraception. One of the following methods is acceptable as the sole method of contraception if there is indisputable data that it is >99% effective, otherwise it should be used with a barrier method (condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository): Documented tubal ligation. Documented placement of an IUD or IUS. Male partner sterilisation prior to the female subject's entry into the study and is the sole partner for that female subject.
- No abnormality on relevant clinical examination or clinical chemistry or haematology examination at the pre-study medical examination.
- A normal 12-lead ECG at the pre-study medical examination
- A negative pre-study Hepatitis B, Hepatitis C, and HIV antibody result at screening.
- A negative pre-study urine drug screen.
- A negative screen for alcohol.
- Subjects must smoke <10 cigarettes per day.
- The subject is able to understand and comply with the study and it's restrictions.
- An unwillingness of the male subject to use a double-barrier method of contraception.
- Female subject is pregnant or lactating.
- Female subjects using hormonal contraceptive precautions including progesterone-coated IUD and oral contraceptives.
- Female subjects using hormonal replacement therapy.
- History of alcohol/drug abuse or dependence within 12 months of the study
- The subject has a positive pre-study urine drug/ urine alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Weekly alcohol intake of more than 21 units or an average daily intake of greater than three units (for male subjects) or weekly alcohol intake more than 14 units or an average daily intake of greater than two units (for female subjects).
- The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug(whichever is longer) prior to the first dose of current study medication.
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- History of sensitivity to any of the study medications, or components thereof.
- Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period.
- History of hypersensitivity to lamotrigine or GW273225.
- History of clinically relevant skin rashes and allergies that, in the opinion of the investigator, might interfere with the conduct of the study.
- Subject has current or past history of seizure disorder or brain injury, or any condition which, in the opinion of the investigator, predisposes to seizure; subject treated with other medications or treatment regimens that lower seizure threshold; subject undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00501865
|GSK Investigational Site
|Cambridge, Cambridgeshire, United Kingdom, CB3 7TR |
||GSK Clinical Trials
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 13, 2007
||May 31, 2012
||United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration
Keywords provided by GlaxoSmithKline:
quantitative pharmacokinetic analysis,
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 10, 2014
Affective Disorders, Psychotic
Central Nervous System Diseases
Nervous System Diseases